Research analysts at Cantor Fitzgerald assumed coverage on shares of Amedisys (NASDAQ:AMED) in a research report issued on Thursday. The brokerage set a “neutral” rating and a $117.00 price target on the health services provider’s stock. Cantor Fitzgerald’s price objective indicates a potential downside of 2.50% from the company’s previous close.

Other equities research analysts have also issued research reports about the company. Canaccord Genuity assumed coverage on Amedisys in a research note on Thursday. They set a “neutral” rating and a $117.00 price target for the company. BidaskClub lowered Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. Bank of America lifted their price target on Amedisys from $73.00 to $78.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 5th. ValuEngine raised Amedisys from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 30th. Finally, Robert W. Baird lifted their price target on Amedisys from $67.00 to $72.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 5th. Five equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $83.23.

AMED stock traded down $1.54 during mid-day trading on Thursday, hitting $120.00. 306,019 shares of the stock were exchanged, compared to its average volume of 305,160. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.30. Amedisys has a 12 month low of $45.60 and a 12 month high of $126.30. The firm has a market cap of $3.98 billion, a P/E ratio of 54.30, a price-to-earnings-growth ratio of 1.97 and a beta of 0.99.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Tuesday, July 31st. The health services provider reported $1.00 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.78 by $0.22. Amedisys had a return on equity of 20.11% and a net margin of 4.46%. The firm had revenue of $411.60 million during the quarter, compared to analyst estimates of $403.62 million. During the same quarter in the previous year, the company posted $0.62 earnings per share. research analysts expect that Amedisys will post 3.41 EPS for the current fiscal year.

In other news, insider David B. Pearce sold 398 shares of the business’s stock in a transaction dated Wednesday, July 25th. The stock was sold at an average price of $94.18, for a total value of $37,483.64. Following the completion of the sale, the insider now owns 12,216 shares of the company’s stock, valued at approximately $1,150,502.88. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 2.60% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Amalgamated Bank lifted its stake in shares of Amedisys by 13.7% in the 2nd quarter. Amalgamated Bank now owns 4,667 shares of the health services provider’s stock valued at $399,000 after acquiring an additional 563 shares during the last quarter. Piedmont Investment Advisors LLC lifted its stake in shares of Amedisys by 9.3% in the 2nd quarter. Piedmont Investment Advisors LLC now owns 6,668 shares of the health services provider’s stock valued at $570,000 after acquiring an additional 567 shares during the last quarter. Metropolitan Life Insurance Co. NY lifted its stake in shares of Amedisys by 6.9% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 9,282 shares of the health services provider’s stock valued at $793,000 after acquiring an additional 596 shares during the last quarter. Xact Kapitalforvaltning AB lifted its stake in shares of Amedisys by 14.1% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 4,851 shares of the health services provider’s stock valued at $415,000 after acquiring an additional 600 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. lifted its stake in shares of Amedisys by 5.9% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 14,132 shares of the health services provider’s stock valued at $1,208,000 after acquiring an additional 783 shares during the last quarter. 93.36% of the stock is owned by institutional investors.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Read More: Leveraged Buyout (LBO) Explained

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.